Compare Manchester United PLC (MANU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Manchester United PLC trades at $20.51 (market cap $3.51B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.9× Manchester United PLC's market cap, and Manchester United PLC pays a 1.26% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MANU | XBI | |
|---|---|---|
Market Cap | $3.51B | $10.11B |
Volume | 412,769 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $24.19 | $169.55 |
52-Week Low | $15.20 | $104.99 |
Typical Hold Time | 109 Days | 38 Days |
Enterprise Value | $4.33B | — |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $20.51, up 1.28% with a bearish technical outlook. The company reported mixed Q4 2026 results, missing EPS estimates but beating revenue expectations. Despite posting a net loss of $33.02M in 2025, revenue grew to $666.51M. Analyst sentiment is divided with 40% buy ratings, while institutional ownership shows confidence with Gabelli Funds increasing its stake by 26.2% in Q1 2026.
MANU presents a speculative opportunity given its discounted valuation relative to franchise worth, but faces significant profitability challenges. The stock's upside depends on operational improvements and Champions League performance, while persistent losses and high debt levels remain key risks for investors.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
